WE ARE ON A MISSION
TO UNLOCK THE POWER OF CELLULAR SIGNALING TO TACKLE THE WORLD'S TOUGHEST HEALTH CHALLENGES
We think about disease triggers and chronic disease a little differently than many folks.
Good health is dependent on successful signaling within and between cells so that normal metabolic functions can work efficiently. A disruption of that signaling, regardless of the triggering event, can lead to disease.
Our focus is on identifying therapeutic agents that can restore cell signaling and consequently restore health. Our search for such agents had led us to discover a number of naturally occurring molecules that, when used in unusually low doses, successfully interrupt disease processes, allow the body to heal and do not have other adverse effects.
That's what we call Nanodosing.
OUR VALUES
We believe the secret sauce for creating patient solutions comes from the culture that we create inside our organization. Through the values that we hold as our foundation, we are building a patient-centered culture. At the heart of Nanodose Therapeutics is an unwavering belief that we can and need to make an impact in patients’ lives. It’s what motivates every day, and it shows in our actions.
We are not content with the status
quo. We take pride in dreaming about and looking for the next innovation that can help and equip patients to tackle the hardest conditions. It is our boldness and disregard for the problems of the present that motivates us to want and achieve more. This allows us to bring new and better products to patients – faster.
We look
for what's possible
In developing and
delivering effective medications that address chronic conditions, we priortize and focus on practical outcomes and patient well-being. We embrace cutting-edge research and technology to accelerate progress and ensure that every initiative moves towards tangible, impactful outcomes.
We are focused on results
By focusing on the power
of many versus the power of one,
we can leverage the unique strengths and talents of others to find solutions for tough healthcare and development challenges. We welcome disagreement, diverse thought, and conflict as these are the building blocks for growth and the best possible output. We’re not just content having a team – we value the high-performing team.
We ensure safety and integrity
OUR STRATEGY
We are focused on developing our lead candidate, NanoSLO, for the treatment of chronic traumatic brain injury (cTBI). We believe NanoSLO will be the first pharmaceutical product to treat the millions of people suffering from this debilitating disease. We will pursue additional indications to help patients suffering from Alzheimer's Disease, strokes, and other challenging neurodegenerative disorders. We possess the worldwide rights for the development of NanoSLO as the first step in that mission.
STRATEGIC IMPERATIVES
TAKE NANOSLO INTO THE CLINIC
A major goal for NanoSLO is to ensure that the product is in the clinic in 2026. In Australia we expect to launch a six-month randomized trial that will examine both biological and behavioral safety in patients with chronic TBI that will provide evidence of safety and may provide indications of efficacy prior to launching a Phase II efficacy trial in the US, Australia and other key markets.
DEVELOP ADDITIONAL FORMULATIONS FOR NANOSLO
We are developing other formulations of NanoSLO to allow for better product performance and different patient applications such as dementia, Alzheimer's Disease as well as applications outside neurology..
SEEK STRATEGIC PARTNERSHIPS
We look for strategic partnerships with biopharmaceutical companies, academic institutions, and non-profit organizations to develop and commercialize NanoSLO. These partnerships could provide significant funding to advance the development of NanoSLO and allow us to benefit from the expertise of our partners.